Knight Therapeutics Inc. (GUD.TO)
| Previous Close | 4.9600 |
| Open | 4.9700 |
| Bid | 4.9300 x 0 |
| Ask | 4.9500 x 0 |
| Day's Range | 4.9400 - 4.9700 |
| 52 Week Range | 4.9200 - 6.2000 |
| Volume | |
| Avg. Volume | 108,657 |
| Market Cap | 562.953M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 15.49 |
| EPS (TTM) | 0.3190 |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.09 |
- Simply Wall St.
While insiders own 21% of Knight Therapeutics Inc. (TSE:GUD), retail investors are its largest shareholders with 56% ownership
Key Insights Significant control over Knight Therapeutics by retail investors implies that the general public has more...
- GlobeNewswire
Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call
MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 23, 2023 Time: 8:30 a.m. ET Telephone: Toll
- The Motley Fool
4 Biotech Stocks That Could Break Through the Market
Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon. The post 4 Biotech Stocks That Could Break Through the Market appeared first on The Motley Fool Canada.
